Overview

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

This study is to evaluate the safety/tolerability and pharmacokinetics of the combinations of gemigliptin 50mg and metformin HCl extended release 500mg in comparison to each component administered alone in healthy male volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

LG Life Sciences

Treatments:

Metformin